Guyana vs Uruguay: HIV/AIDS deaths averted by antiretroviral therapy
Guyana
512.85 deaths
in 2024
Uruguay
516 deaths
in 2022
Guyana rank
93rd
Uruguay rank
91st
HIV/AIDS deaths averted by antiretroviral therapy over time
- Guyana
- Uruguay
How they compare
Uruguay currently reports 516 deaths against 512.85 deaths in Guyana, a difference of 3.15 deaths.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Uruguay ahead.
Guyana ranks 93rd and Uruguay ranks 91st of 157 countries.
Across the 4 decades both report, Guyana averaged higher in 1 and Uruguay in 3.
Head to head by decade
| Decade | Guyana | Uruguay | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 25 deaths | 25 deaths | Uruguay |
| 2000s | 139.91 deaths | 166.5 deaths | 26.59 deaths | Uruguay |
| 2010s | 424.71 deaths | 364 deaths | 60.71 deaths | Guyana |
| 2020s | 486.18 deaths | 487 deaths | 0.8223 deaths | Uruguay |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Guyana or Uruguay?
- Uruguay, at 516 deaths against 512.85 deaths in Guyana as of 2022.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Guyana and Uruguay?
- 3.15 deaths, with Uruguay ahead.
- How many years of comparable data are there for Guyana and Uruguay?
- 33 years are reported by both, from 1990 to 2022.
- How do Guyana and Uruguay rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Guyana ranks 93rd and Uruguay ranks 91st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.